AJMC Contributor

Higher CONUT nutritional scores strongly predict poorer survival and greater lung function decline in PPF, highlighting malnutrition as a key modifiable risk factor.

Levels of GDF15 and OPN can accurately distinguish uterine sarcoma from benign leiomyoma, with GDF15 also serving as an independent predictor of disease progression.

The algorithm could outperform existing noninvasive tools for identifying advanced fibrosis in MASH without producing indeterminate results.

AI, especially deep learning applied to blood smear imaging, can greatly improve the speed and accuracy of leukemia detection and subtype classification.

The analysis found that zanubrutinib provides similar progression-free survival to fixed-duration venetoclax plus ibrutinib but with consistently fewer serious side effects, suggesting a more favorable overall safety profile.

Resmetirom improved MASH and fibrosis consistently across patients regardless of GLP-1 or SGLT2 inhibitor use, with outcomes further enhanced in those who achieved at least 5% weight loss.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A novel RTEL1 nonsense mutation was identified in a woman with multigenerational familial pulmonary fibrosis (PF), expanding the genetic spectrum of telomere-related lung disease and underscoring the importance of genetic testing in suspected inherited interstitial lung disease (ILD).

A wide range of non-invasive tests reliably reflected semaglutide-related improvements in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

Routine flow cytometry can reliably track chimeric antigen receptor (CAR) T-cell expansion and persistence in aggressive large B-cell lymphoma (LBCL).

The case shows how such cardiac involvement can mimic neurologic disease and demand complex, multidisciplinary management.

Researchers have developed a machine learning model that reliably predicts pulmonary hypertension (PH) risk in patients with chronic kidney disease (CKD).

Bariatric surgery halves mortality and reduces liver, heart, and kidney complications in steatotic liver disease vs nonsurgical care.

Overlapping metabolic mechanisms drive both chronic kidney disease (CKD) and valvular heart disease (VHD), a new review outlined.

Myeloproliferative neoplasms–unclassifiable (MPN-U), show distinct genetic and clinical patterns that differentiate them from essential thrombocythemia.

Synovial sarcoma—a rare, aggressive soft tissue cancer—can present as a painless hand swelling that mimics a harmless lesion, underscoring the need for early recognition and improved diagnostic access in low-resource settings.

CD45 + C1q + CCR8+ cells were found to be a novel immune-cell subset associated with kidney disease severity and progression risk.

Patients with fatty liver disease are significantly more likely to develop kidney stones, a national study found.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

Researchers developed a first-of-its-kind panel to track receptor expression and predict therapy response.

The study highlighted pain, fatigue, and functional status as key early warning signs.

Emotional well-being and social engagement significantly impact quality of life for patients with soft tissue sarcoma post-surgery.

Weight loss medications show promise in improving liver health for those with chronic liver conditions, a review found.

Electronic health record (EHR)–based “e-phenotypes” combining lab data, coding, and AI could dramatically improve early detection and management of chronic kidney disease.

The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.

A phase 1b trial of tarlatamab plus PD-L1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) showed a median overall survival of 25.3 months with manageable safety.

Four autophagy-related variants in CDKN2A and BCL2 may increase susceptibility to chronic lymphocytic leukemia (CLL).

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.

As oncology continues to move more toward precision medicine, tools like EVOFLUx may offer a more personalized roadmap from diagnosis to treatment.